DX
DXR.US Daxor Corporation
- Market cap
- USD 49.5M
- P/E
- 7.7x
- P/B
- 0.95x
- ROE
- -25.6%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 1 quarter up to Jun 2026.
Is DXR.US undervalued?
Graham numberDXR.US trades 42.9% below its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Daxor Corporation fundamental analysis
No fundamental analysis for Daxor Corporation yet.
Daxor Corporation stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Daxor Corporation
Daxor Corporation engages in medical instrumentation and biotechnology operations. It develops the BVA-100 Blood Volume Analyzer, an instrument that measures human blood volume, in conjunction with Volumex, a single-use radiopharmaceutical diagnostic injection and collection kit. The company was formerly known as Idant Corporation and changed its name to Daxor Corporation in May 1973. Daxor Corporation was incorporated in 1971 and is headquartered in Oak Ridge, Tennessee. Da…
Full company profileDaxor Corporation financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 1 quarter up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Daxor Corporation annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 1.84M | -1.01M | -918K | -115K | -996K | 5.82M | 6.31M | 34.6M | 2.13M | 503K | 92.1K |
| Gross Profit | 1.56M | -1.01M | -918K | -115K | -996K | 5.82M | 6.31M | 34.4M | 2.13M | 189K | -241K |
| Operating Income | 1.47M | -1.14M | -1.10M | -496K | -1.73M | 4.75M | 5.25M | 330K | 621K | 9.19M | -13.2M |
| EBITDA | 1.47M | -1.14M | -1.10M | -496K | -1.73M | 4.75M | 5.25M | 1.12M | 2.06M | 9.19M | -13.2M |
| Net Income | 1.46M | -1.24M | -886K | -496K | -1.71M | 4.75M | 5.18M | 281K | 536K | 9.17M | -13.2M |
| EPS | 0.38 | -0.33 | -0.24 | -0.12 | -0.43 | 1.18 | 0.60 | 0.06 | 0.11 | 1.84 | -2.66 |
| Balance Sheet | |||||||||||
| Total Assets | 20.6M | 19.3M | 17.6M | 14.2M | 16.6M | 25.0M | 30.3M | 34.9M | 36.6M | 46.0M | 51.9M |
| Total Liabilities | 5.28M | 5.55M | 4.56M | 1.44M | 878K | 3.83M | 1.29M | 859K | 840K | 123K | 23.6K |
| Shareholders' Equity | 15.3M | 13.8M | 13.1M | 12.8M | 15.7M | 21.2M | 29.0M | 34.0M | 35.8M | 45.9M | 51.8M |
| Cash & Short-term Investments | 2.18M | 1.09M | - | - | 618K | 711K | - | - | - | - | 5.79M |
| Total Debt | 2.80M | 4.33M | 4.45M | 1.34M | 171K | 3.02M | 1.23M | 756K | 730K | 112K | - |
| Cash Flow | |||||||||||
| Operating Cash Flow | 1.59M | -1.17M | -1.32M | 3.11M | -2.45M | -2.76M | -769K | -3.66M | 25.7K | -604K | -10.0M |
| Capital Expenditure | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 3.00 | 4.00 | 1.00 | 4.00 | 0.00 | 0.00 |
| Free Cash Flow | 1.59M | -1.17M | -1.32M | 3.11M | -2.45M | -2.76M | -769K | -3.66M | 25.7K | -604K | -10.0M |
| Ratios | |||||||||||
| ROE | 9.5% | -9.0% | -6.8% | -3.9% | -10.9% | 22.4% | 17.9% | 0.8% | 1.5% | 20.0% | -25.6% |
| ROA | 7.1% | -6.4% | -5.0% | -3.5% | -10.3% | 19.0% | 17.1% | 0.8% | 1.5% | 19.9% | -25.5% |
| Net Profit Margin | 79.3% | - | - | - | - | 81.6% | 82.1% | 0.8% | 25.2% | 1,821.5% | -14,382.9% |
| Debt to Equity | 0.18x | 0.32x | 0.34x | 0.11x | 0.01x | 0.14x | 0.04x | 0.02x | 0.02x | 0.00x | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Daxor Corporation dividends
- Dividend yield
- -
- Forward dividend
- -
- Payout ratio
- -
- Ex-dividend date
- Jan 5, 2018
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | - | - | - |
| 2024 | - | - | - |
| 2023 | - | - | - |
| 2022 | - | - | - |
| 2021 | - | - | - |
| 2020 | - | - | - |
| 2019 | - | - | - |
| 2018 | - | - | - |
| 2017 | USD 112K | 0.03 | - |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Who owns Daxor Corporation
- Insiders 49.50%
- Institutions 7.76%
- Public & others 42.75%
- Shares outstanding 5.84M
- Free float 2.90M
Top funds holding DXR.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Vanguard MStar Total Stk Mkt Idx Invest | 49.1K | 0.84% | +0.57% | Sep 2026 |
| Gabelli Global Mini Mites I | 400.00 | 0.01% | 0.00% | Jun 2026 |
Top institutions holding DXR.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Thompson, Siegel & Walmsley LLC | 242K | 4.14% | 0.00% | Sep 2026 |
| Vanguard Capital Management, LLC | 48.8K | 0.84% | +1.14% | Jun 2026 |
| Aristides Capital LLC | 41.7K | 0.71% | -0.01% | Jun 2026 |
| Renaissance Technologies Corp | 29.4K | 0.50% | +5.03% | Jun 2026 |
| Susquehanna International Group, LLP | 27.1K | 0.46% | +97.75% | Jun 2026 |
| NANO CAP NEW MILLENNIUM GROWTH FUND L P | 12.5K | 0.21% | 0.00% | Jun 2026 |
| Crescent Grove Advisors, LLC | 12.4K | 0.21% | +15.85% | Jun 2026 |
| SBI Securities Co Ltd | 3.13K | 0.05% | +0.10% | Jun 2026 |
| Morgan Stanley - Brokerage Accounts | 3.09K | 0.05% | 0.00% | Jun 2026 |
| Vanguard Fiduciary Trust Co | 1.04K | 0.02% | 0.00% | Jun 2026 |
| Advisor Group Holdings, Inc. | 500.00 | 0.01% | 0.00% | Jun 2026 |
| Tower Research Capital LLC | 305.00 | 0.01% | +179.82% | Jun 2026 |
| UBS Group AG | 172.00 | 0.00% | 0.00% | Jun 2026 |
| JPMorgan Chase & Co | 6.00 | 0.00% | +500.00% | Jun 2026 |
| Wells Fargo & Co | 0.00 | 0.00% | 0.00% | Jun 2026 |
| Empirical Financial Services, LLC | 0.00 | 0.00% | -100.00% | Jun 2026 |
Daxor Corporation company profile
- Company name
- Daxor Corporation
- Ticker
- DXR.US
- Exchange
- USA Stocks
- Listed since
- Mar 17, 1992
- Sector
- Healthcare
- Industry
- Health Care Equipment & Supplies
- Fiscal year end
- December
- Address
- 109 Meco Lane, Oak Ridge, TN, United States, 37830
- Phone
- 865 425 0555
- Website
- daxor.com
About Daxor Corporation
Daxor Corporation engages in medical instrumentation and biotechnology operations. It develops the BVA-100 Blood Volume Analyzer, an instrument that measures human blood volume, in conjunction with Volumex, a single-use radiopharmaceutical diagnostic injection and collection kit. The company was formerly known as Idant Corporation and changed its name to Daxor Corporation in May 1973. Daxor Corporation was incorporated in 1971 and is headquartered in Oak Ridge, Tennessee. Daxor Corporation operates as a subsidiary of Estate Of Joseph Feldschuh.
Daxor Corporation management
7- Mr. Michael Richard FeldschuhChairman, President & CEO · born 1969
- Mr. Robert J. Michel CPA, M.B.A.CFO, Chief Compliance Officer & Corporate Secretary · born 1957
- Mr. Jonathan Adam FeldschuhChief Scientific Officer & Director · born 1965
- Dr. John Lynn Jefferies FACC, M.B.A., M.D., M.P.H.Chief Medical Officer · born 1970
- Ms. Linda CooperVice President of Development & Operations
- Ms. Kathryn A. KornafelSenior VP of Marketing & Commercial Development
- Ms. Annette Plishka B.S.N.Senior Vice President of Commercialization